Literature DB >> 3114439

Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions.

J M Trugman, G F Wooten.   

Abstract

The relative roles of D1 and D2 dopamine receptor stimulation in mediating the antiparkinsonian effects of dopaminergic drugs remain unclear. To determine the functional metabolic consequences of selective dopamine receptor stimulation, we used 2-deoxyglucose (2-DG) autoradiography to examine the effects of the D1 agonist SKF-38393 and the D2 agonist LY-171555 on regional cerebral glucose utilization (RCGU) in rats with unilateral 6-hydroxydopamine (6-OHDA) substantia nigra lesions. SKF-38393 (0.5-25.0 mg/kg) and LY-171555 (0.01-5.0 mg/kg) produced indistinguishable behavioral responses, including vigorous contralateral rotation. Treatment with each drug similarly increased glucose utilization, dose-dependently, in the parafascicular thalamus, subthalamic nucleus, deep layers of the superior colliculus, and lateral midbrain reticular formation ipsilateral to the nigral lesion; glucose utilization was decreased in the ipsilateral lateral habenula. By contrast, the D1 and D2 agonists differentially altered glucose utilization in the entopeduncular nucleus (EP) and the substantia nigra pars reticulata (SNr). SKF-38393, 5.0 and 25.0 mg/kg, increased glucose utilization 127 and 275%, respectively, in the pars reticulata ipsilateral to the lesion. LY-171555, 1.0 and 5.0 mg/kg, caused maximal contralateral turning, yet did not alter glucose utilization in the ipsilateral SNr. The glucose utilization response of the ipsilateral EP paralleled that of the SNr demonstrating large increases following administration of SKF-38393 and minimal change following the use of LY-171555. The results demonstrate that the selective D1 agonist reproduces the marked glucose utilization increases (2-3-fold above control values) in the EP and SNr that were previously observed using L-DOPA and apomorphine in this model, whereas the selective D2 agonist does not.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114439      PMCID: PMC6569153     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  16 in total

1.  Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission.

Authors:  R T Fremeau; G E Duncan; M G Fornaretto; A Dearry; J A Gingrich; G R Breese; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease.

Authors:  D S Kreiss; C W Mastropietro; S S Rawji; J R Walters
Journal:  J Neurosci       Date:  1997-09-01       Impact factor: 6.167

Review 3.  Striatal dopamine in motor activation and reward-mediated learning: steps towards a unifying model.

Authors:  J Wickens
Journal:  J Neural Transm Gen Sect       Date:  1990

4.  Blockade ofNMDA receptors differentially affectsD-1 andD-2 mediated turning behavior in the 6-hydroxydopamine model of Parkinson.

Authors:  M Morelli; S Fenu; A Pinna; A Cozzolino; G Di Chiara
Journal:  Amino Acids       Date:  1991-06       Impact factor: 3.520

5.  D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats.

Authors:  Abesh Kumar Bhattacharjee; Lisa Chang; Ho-Joo Lee; Richard P Bazinet; Ruth Seemann; Stanley I Rapoport
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

6.  Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.

Authors:  Jean-Christophe Corvol; Marie-Paule Muriel; Emmanuel Valjent; Jean Féger; Naïma Hanoun; Jean-Antoine Girault; Etienne C Hirsch; Denis Hervé
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

7.  Differential regulation of neuropeptide mRNA expression in intrastriatal striatal transplants by host dopaminergic afferents.

Authors:  K Campbell; K Wictorin; A Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

8.  Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa.

Authors:  R Bordet; S Ridray; S Carboni; J Diaz; P Sokoloff; J C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function.

Authors:  K J Black; M H Gado; J S Perlmutter
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

Review 10.  An update on the connections of the ventral mesencephalic dopaminergic complex.

Authors:  L Yetnikoff; H N Lavezzi; R A Reichard; D S Zahm
Journal:  Neuroscience       Date:  2014-04-13       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.